Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14303556 | 0.85 | CHRM1 (0.40) | SLC6A5CHRM1HRH3SIGMAR1 | |
| SCHEMBL8278776 | 0.83 | SLC6A5 (0.49) | CA1CA2CA12CA9OPRM1 | |
| SCHEMBL23166392 | 0.83 | SMYD3 (0.41) | CHRM1HRH3SIGMAR1 | |
| SCHEMBL10076724 | 0.83 | CHRM1 (0.40) | CA1CA2CA12CA9OPRM1 | |
| SCHEMBL13207164 | 0.82 | EPHX2 (0.50) | CA1CA2CA12CA9 | |
| SCHEMBL30528703 | 0.81 | CA1 (0.54) | CA1CA2CA12CA9CHRM1 | |
| SCHEMBL30636651 | 0.81 | CA1 (0.54) | CA1CA2CA12CA9CHRM1 | |
| SCHEMBL12332584 | 0.81 | POLB (0.44) | CA1CA2CA12CA9OPRM1 | |
| SCHEMBL8256972 | 0.79 | HRH3 (0.53) | CA1CA2CA12CA9HRH3 | |
| SCHEMBL30636641 | 0.77 | CA1 (0.53) | CA1CA2CA12CA9CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | CA1 4562/4885CA2 2331/4885CA12 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.